Drugs for Lingual-Facial-Buccal Dyskinesia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 147)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Aripiprazole |
Approved, Investigational |
Phase 4 |
|
129722-12-9 |
60795 |
Synonyms:
7-(4-(4-(2,3-Dichlorophenyl)-1-piperazinyl)butyloxy)-3,4-dihydro-2(1H)-quinolinone
Abilify
ABILIFY MAINTENA
ABILIFY MAINTENA KIT
ABILIFY MYCITE KIT
Abilify®|Aripiprex®|Aristada® (aripiprazole lauroxil)|OPC 14597|OPC-14597
Abilitat
Aripiprazol
|
ARIPIPRAZOLE
Aripiprazolum
ARIPIPREX
OPC 14597
OPC 31
OPC-14597
OPC-31
|
|
2 |
|
Varenicline |
Approved, Investigational |
Phase 4 |
|
249296-44-4 |
5310966 |
Synonyms:
6,7,8,9-Tetrahydro-6,10-methano-6H-pyrazino(2,3-H)benzazepine
7,8,9,10-Tetrahydro-6,10-methano-6H-pyrazino(2,3-H)(3)benzazepine
Champix
Champix®|Chantix®|compound 9a [PMID: 16171993]|CP 526555
Chantix
CP-526,555
|
CP-526555
Tartrate, varenicline
Vareniclina
VARENICLINE
Varenicline tartrate
Vareniclinum
|
|
3 |
|
Levetiracetam |
Approved |
Phase 4 |
|
102767-28-2 |
441341 5284583 |
Synonyms:
AGB-101
alpha Ethyl 2 oxo 1 pyrrolidineacetamide
alpha-Ethyl-2-oxo-1-pyrrolidineacetamide
DESITREND
e Keppra
ELEPSIA XR
Etiracetam
Etiracetam, R isomer
Etiracetam, R-isomer
Etiracetam, S isomer
Etiracetam, S-isomer
Keppra
KEPPRA XR
Keppra®|Spritam®|UCB L059|UCB-L 059
LEVETIRACETAM
Levetiracetam [INN]
LEVETIRACETAM IN SODIUM CHLORIDE
|
Levetiracetame
Levetiracetamum
Levetiracetamum [INN-Latin]
Levitiracetam
MATEVER
N03AX14
R-Isomer etiracetam
S-Isomer etiracetam
SPRITAM
UCB brand OF levetiracetam
Ucb L059
Ucb L060
UCB-22059
Ucb-L059
UcbL060
Ucb-L060
|
|
4 |
|
Carbidopa |
Approved |
Phase 4 |
|
28860-95-9 |
34359 38101 |
Synonyms:
(-)-L-a-Hydrazino-3,4-dihydroxy-a-methylhydrocinnamate
(-)-L-a-Hydrazino-3,4-dihydroxy-a-methylhydrocinnamic acid
(-)-L-alpha-Hydrazino-3,4-dihydroxy-alpha-methylhydrocinnamate
(-)-L-alpha-Hydrazino-3,4-dihydroxy-alpha-methylhydrocinnamic acid
(-)-L-ALPHA-HYDRAZINO-3,4-DIHYDROXY-ALPHA-METHYLHYDROCINNAMIC ACID MONOHYDRATE
(-)-L-Α-hydrazino-3,4-dihydroxy-α-methylhydrocinnamate
(-)-L-Α-hydrazino-3,4-dihydroxy-α-methylhydrocinnamic acid
(2S)-3-(3,4-DIHYDROXYPHENYL)-2-HYDRAZINYL-2-METHYLPROPANOIC ACID HYDRATE
(2S)-3-(3,4-DIHYDROXYPHENYL)-2-HYDRAZINYL-2-METHYLPROPANOIC ACID MONOHYDRATE
(AlphaS)-a-hydrazino-3,4-dihydroxy-a-methylbenzenepropanoate
(AlphaS)-a-hydrazino-3,4-dihydroxy-a-methylbenzenepropanoic acid
(AlphaS)-alpha-hydrazino-3,4-dihydroxy-alpha-methylbenzenepropanoate
(AlphaS)-alpha-hydrazino-3,4-dihydroxy-alpha-methylbenzenepropanoic acid
(ALPHAS)-ALPHA-HYDRAZINO-3,4-DIHYDROXY-ALPHA-METHYLBENZENEPROPANOIC ACID MONOHYDRATE
(AlphaS)-α-hydrazino-3,4-dihydroxy-α-methylbenzenepropanoate
(AlphaS)-α-hydrazino-3,4-dihydroxy-α-methylbenzenepropanoic acid
(S)-(−)-carbidopa
(S)-(-)-Carbidopa
(S)-(-)-CARBIDOPA HYDRATE
(S)-(−)-CARBIDOPA HYDRATE
(S)-Carbidopa
(S)-CARBIDOPA HYDRATE
|
(αS)-α-hydrazino-3,4-dihydroxy-α-methylbenzenepropanoic acid
Carbidopa
Carbidopa (anhydrous)
CARBIDOPA ANHYDROUS
CARBIDOPA HYDRATE
CARBIDOPA MONOHYDRATE
Carbidopa, (R)-isomer
Carbidopa, (S)-isomer
Carbidopum
CARBIDOPUM MONOHYDRICUM
CDP536
Duodopa®|Lodosyn®|MK 486
L-3-(3,4-Dihydroxyphenyl)-2-methyl-2-hydrazinopropionate
L-3-(3,4-Dihydroxyphenyl)-2-methyl-2-hydrazinopropionic acid
L-ALPHA-(3,4-DIHYDROXYBENZYL)-ALPHA-HYDRAZINOPROPIONIC ACID MONOHYDRATE
L-alpha-Methyldopahydrazine
L-a-Methyldopahydrazine
Lodosin
Lodosyn
L-Α-methyldopahydrazine
Methyldopahydrazine
MK-486
|
|
5 |
|
Amisulpride |
Approved, Investigational |
Phase 4 |
|
71675-85-9, 53583-79-2 |
2159 |
Synonyms:
(±)-amisulpride|Barhemsys®
(±)-AMISULPRIDE
4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-2-methoxybenzamide
4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-O-anisamide
4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulphonyl)-2-methoxybenzamide
4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulphonyl)-O-anisamide
5-(Ethanesulfonyl)-N-[(1-ethylpyrrolidin-2-yl)methyl]-2-methoxybenzene-1-carboximidate
5-(Ethanesulphonyl)-N-[(1-ethylpyrrolidin-2-yl)methyl]-2-methoxybenzene-1-carboximidate
5-(Ethanesulphonyl)-N-[(1-ethylpyrrolidin-2-yl)methyl]-2-methoxybenzene-1-carboximidic acid
Aminosultopride
Amisulprida
Amisulpride
Amisulpridum
APD421
APD-421
|
Barnetil
DAN-2163
Deniban
N-(Ethyl-1-pyrrolidinyl- 2-methyl)methoxy-2-ethylsulfonyl-5-benzamide
Solian
SOLIAN 100
SOLIAN 200
SOLIAN 400
SOLIAN 50
Sultopride
Sultopride HCL
Sultopride hydrochloride
Sultopridum
Sultroprida
|
|
6 |
|
Olanzapine |
Approved, Investigational |
Phase 4 |
|
132539-06-1 |
135398745 4585 |
Synonyms:
2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno(2,3-b)(1,5)benzodiazepine
2-METHYL-4-(4-METHYL-1-PIPERAZINYL)-10H-THIENO[2,3-B][1,5]BENZODIAZEPINE
ARKOLAMYL
Lanzac
LY170053
LY-170053
LY-170053|Zyprexa®
Olansek
OLANZAPIN
Olanzapina
|
OLANZAPINE
Olanzapine pamoate
Olanzapinum
Symbyax
ZALASTA
Zolafren
Zydis
Zyprexa
Zyprexa intramuscular
Zyprexa zydis
|
|
7 |
|
Galantamine |
Approved |
Phase 4 |
|
357-70-0, 1953-04-4 |
9651 |
Synonyms:
(-)-GALANTHAMINE
ACUMOR XL
CONSION XL
ELMINO XL
Galantamin
Galantamina
Galantamine
Galanthamine
Galanthamine hydrobromide
galanthamine|Razadyne®
GALSYA XL
GALZEMIC XL
GATALIN XL
GAZYLAN XL
|
Jilkon
LOTPROSIN XL
LUVENTA XL
Lycoremin
Lycoremine
Nivalin
Nivaline
NSC-100058
Ortho mcneil neurologics brand OF galantamine
Ortho-mcneil neurologics brand OF galantamine
Razadyne
Reminyl
REMINYL XL
ZEEBRAL XL
|
|
8 |
|
Risperidone |
Approved, Investigational |
Phase 4 |
|
106266-06-2 |
5073 |
Synonyms:
Belivon
Buspirone
Consta, risperdal
LY03004
LY-03004
N05AX08
Okedi®|R-64-766|R-64766|Risperdal®
PERSERIS KIT
R-64,766
R-64766
R-64-766
RCN3028
RCN-3028
Rispen
Risperdal
Risperdal consta
RISPERDAL CONSTA LONG ACTING
|
RISPERDAL M
Risperdal m-tab
RISPERDAL QUICKLET
RISPERDONE
Risperidal
Risperidal M-Tab
Risperidona
Risperidona [Spanish]
Risperidone
Rispéridone
Risperidonum
Risperidonum [Latin]
Risperin
Rispolept
Rispolin
Sequinan
Spiron
|
|
9 |
|
Zonisamide |
Approved, Investigational |
Phase 4 |
|
68291-97-4 |
5734 |
Synonyms:
1,2-Benzisoxazole-3-methanesulfonamide
1,2-Benzisoxazole-3-methanesulphonamide
3 Sulfamoylmethyl 1,2 benzisoxazole
3-(Sulfamoylmethyl)-1,2-benzisoxazole
3-(Sulphamoylmethyl)-1,2-benzisoxazole
3-Sulfamoylmethyl-1,2-benzisoxazole
AD-810
AD-810|CI-912|PD-110843|Zonegran®
Benzo[D]isoxazol-3-yl-methanesulfonamide
Benzo[D]isoxazol-3-yl-methanesulphonamide
CI-912
Elan brand OF zonisamide
|
Exceglan
Excegram
Excegran
PD-110843
Zonegran
Zonisamida
Zonisamida [Spanish]
Zonisamide
Zonisamide monosodium
Zonisamidum
Zonisamidum [Latin]
|
|
10 |
|
Acetylcholine |
Approved, Investigational |
Phase 4 |
|
51-84-3 |
187 |
Synonyms:
[2-(ACETYLOXY)ETHYL]TRIMETHYLAZANIUM
2-(Acetyloxy)-N,N,N-trimethylethanaminium
2-ACETOXYETHYL(TRIMETHYL)AMMONIUM
2-ACETYLOXYETHYL(TRIMETHYL)AMMONIUM
2-ACETYLOXYETHYL(TRIMETHYL)AZANIUM
Acetilcolina cusi
Acetyl choline ion
Acetylcholine
Acetylcholine bromide
Acetylcholine cation
Acetylcholine chloride
Acetylcholine fluoride
Acetylcholine hydroxide
Acetylcholine iodide
Acetylcholine L tartrate
Acetylcholine L-tartrate
Acetylcholine perchlorate
Acetylcholine picrate
Acetylcholine picrate (1:1)
Acetylcholine sulfate (1:1)
ACETYLCHOLINE, ACH
Acetylcholinium: acetyl-choline
|
ACh
ACh|E1001|O-acetylcholine
Alcon brand OF acetylcholine chloride
Azetylcholin
Bournonville brand OF acetylcholine chloride
Bromide, acetylcholine
Bromoacetylcholine
Chloroacetylcholine
Choline acetate
Choline acetate (ester)
Choline acetic acid
Ciba vision brand OF acetylcholine chloride
Cusi, acetilcolina
E1001
Fluoride, acetylcholine
Hydroxide, acetylcholine
Iodide, acetylcholine
Iolab brand OF acetylcholine chloride
L-Tartrate, acetylcholine
Miochol
O-Acetylcholine
Perchlorate, acetylcholine
|
|
11 |
|
Nicotinic Agonists |
|
Phase 4 |
|
|
|
12 |
|
Psychotropic Drugs |
|
Phase 4 |
|
|
|
13 |
|
Antipsychotic Agents |
|
Phase 4 |
|
|
|
14 |
|
Aromatic Amino Acid Decarboxylase Inhibitors |
|
Phase 4 |
|
|
|
15 |
|
Nootropic Agents |
|
Phase 4 |
|
|
|
16 |
|
Dopamine Antagonists |
|
Phase 4 |
|
|
|
17 |
|
Antidepressive Agents |
|
Phase 4 |
|
|
|
18 |
|
Gastrointestinal Agents |
|
Phase 4 |
|
|
|
19 |
|
Omega 3 Fatty Acid |
|
Phase 4 |
|
|
|
20 |
|
Antiemetics |
|
Phase 4 |
|
|
|
21 |
|
Serotonin Uptake Inhibitors |
|
Phase 4 |
|
|
|
22 |
|
Cholinesterase Inhibitors |
|
Phase 4 |
|
|
|
23 |
|
calcium channel blockers |
|
Phase 4 |
|
|
|
24 |
|
abobotulinumtoxinA |
|
Phase 4 |
|
|
|
Synonyms:
ABOBOTULINUMTOXINA
BONT/A
BONTOXILYSIN A
BOTOX
BOTULINUM TOXIN TYPE A
|
BOTULINUM TOXINS, TYPE A
BOTULOTOXIN A
BTX-A
ONABOTULINUMTOXINA
|
|
25 |
|
Botulinum Toxins, Type A |
|
Phase 4 |
|
|
|
26 |
|
Botulinum Toxins |
|
Phase 4 |
|
|
|
27 |
|
Cholinergic Agents |
|
Phase 4 |
|
|
|
28 |
|
Serotonin |
Investigational, Nutraceutical |
Phase 4 |
|
50-67-9 |
5202 |
Synonyms:
3-(2-Aminoethyl)-1H-indol-5-ol
3-(2-Aminoethyl)indol-5-ol
3-(b-Aminoethyl)-5-hydroxyindole
5 Hydroxytryptamine
5-HT
5-HT|serotonin
5-HTA
5-Hydroxy-3-(b-aminoethyl)indole
5-Hydroxyltryptamine
5-Hydroxytriptamine
5-Hydroxytryptamine
5-Hydroxy-tryptamine
|
Antemovis
DS Substance
Enteramin
Enteramine
Hippophaine
Hydroxytryptamine
SEROTONIN
Serotonine
sérotonine
Thrombocytin
Thrombotonin
|
|
29 |
|
Buspirone |
Approved, Investigational |
Phase 3 |
|
36505-84-7 |
2477 |
Synonyms:
8-(4-(4-(2-Pyrimidinyl)-1-piperizinyl)butyl)-8-azaspiro(4,5)decane-7,9-dione
Anxut
Apo buspirone
Apo-buspirone
Apotex brand OF buspirone hydrochloride
Armstrong brand OF buspirone hydrochloride
BCI-024
Bespar
Bristol myers brand OF buspirone hydrochloride
Bristol myers squibb brand OF buspirone hydrochloride
Bristol-myers brand OF buspirone hydrochloride
Bristol-myers squibb brand OF buspirone hydrochloride
Busp
Buspar
Buspar®|MJ-9022-1
Buspiron
Buspirona
Buspirone
Buspirone hydrochloride
Buspironum
Eisai brand OF buspirone hydrochloride
Gen buspirone
Gen-buspirone
Genpharm brand OF buspirone
|
Hexal brand OF buspirone hydrochloride
Hormosan brand OF buspirone hydrochloride
Hydrochloride, buspirone
Lin buspirone
Lin-buspirone
Linson pharma brand OF buspirone hydrochloride
MJ-9022-1
N-(4-(4-(2-Pyrimidinyl)-1-piperazinyl)butyl)-1-cyclopentanediacetamide
Neurosine
Novo buspirone
Novo-buspirone
Novopharm brand OF buspirone hydrochloride
Nu buspirone
Nu pharm brand OF buspirone hydrochloride
Nu-buspirone
Nu-pharm brand OF buspirone hydrochloride
Pharmascience brand OF buspirone hydrochloride
PMS Buspirone
PMS-Buspirone
Ratio buspirone
Ratio-buspirone
Ratiopharm brand OF buspirone hydrochloride
UPSA brand OF buspirone hydrochloride
|
|
30 |
|
Amantadine |
Approved |
Phase 3 |
|
768-94-5 |
2130 |
Synonyms:
1 Aminoadamantane
1-Adamantanamine
1-Adamantylamine
1-Aminoadamantane
AbZ brand OF amantadine hydrochloride
Adamantamine
Adamantanamine
Adamantylamine
Adekin
ADS-5102|Gocovri®|Symadine®|Symmetrel®
AL, amantadin
Aliud brand OF amantadine sulfate
Alliance brand OF amantadine hydrochloride
Aman
Amanta
Amanta hci azu
Amanta sulfate azu
Amantadin al
Amantadin azu
Amantadin neuraxpharm
Amantadin ratiopharm
Amantadin stada
Amantadina
Amantadina juventus
Amantadina llorente
AMANTADINE
Amantadine base
Amantadine HCL
Amantadine hydrochloride
Amantadine sulfate
Amantadinneuraxpharm
Amantadin-neuraxpharm
Amantadinratiopharm
Amantadin-ratiopharm
Amantadinum
Amanta-hci-azu
AmantaHCIAZU
Amantasulfateazu
Amanta-sulfate-azu
Amantidine
Aminoadamantane
Amixx
AZU, amantadin
Azupharma brand OF amantadine hydrochloride
Azupharma brand OF amantadine sulfate
Cerebramed
Ciba geigy brand OF amantadine hydrochloride
Ciba-geigy brand OF amantadine hydrochloride
Desitin brand OF amantadine hydrochloride
Du pont brand OF amantadine hydrochloride
|
Endantadine
endo Brand OF amantadine hydrochloride
Gen amantadine
Gen-amantadine
GenAmantadine
Genpharm brand OF amantadine hydrochloride
Hexal brand OF amantadine sulfate
Hormosan brand OF amantadine sulfate
Hydrochloride, amantadine
Infecto flu
Infecto-flu
InfectoFlu
Infectopharm brand OF amantadine hydrochloride
Infex
Juventus brand OF amantadine hydrochloride
Juventus, amantadina
Krewel brand OF amantadine hydrochloride
Llorente brand OF amantadine hydrochloride
Llorente, amantadina
Mantadine
Mantadix
Merz brand OF amantadine sulfate
Midantan
Neuraxpharm brand OF amantadine sulfate
Neuro hexal brand OF amantadine sulfate
Novartis brand OF amantadine hydrochloride
NSC-341865
Orion brand OF amantadine hydrochloride
Pharmascience brand OF amantadine hydrochloride
Pk-Merz
PMS Amantadine
PMSAmantadine
PMS-Amantadine
Ratiopharm brand OF amantadine hydrochloride
Solvay brand OF amantadine hydrochloride
Stada brand OF amantadine hydrochloride
Stada brand OF amantadine sulfate
Stada, amantadin
Sulfate, amantadine
Symadine
Symmetrel
TCMDC-125869
Thiemann brand OF amantadine hydrochloride
Tregor
Tricyclo[3.3.1.1(3,7)]decan-1-amine
Tricyclo[3.3.1.1(3,7)]decan-1-ylamine
Tricyclo[3.3.1.1(3,7)]decane-1-amine
Viregyt
Virosol
Wiregyt
|
|
31 |
|
Ropinirole |
Approved, Investigational |
Phase 3 |
|
91374-21-9 |
5095 |
Synonyms:
4-(2-(Di-N-propylamino)ethyl)-2(3H)-indolone
GlaxoSmithKline brand OF ropinirole hydrochloride
Requip
Requip®|SK&F-101468-A|SK&F-101468A
Ropinirol
Ropinirole
Ropinirole hydrochloride
Ropinirolum
|
Ropitor
SK And F 101468
SK And F-101,468
SK&F-101468
SK&F-101468A
SK&F-101468-A
SmithKline beecham brand OF ropinirole hydrochloride
|
|
32 |
|
Tetrabenazine |
Approved, Investigational |
Phase 3 |
|
58-46-8 |
6018 |
Synonyms:
1,2,4,6,7,11b-Hexahydro-3-isobutyl-9,10-dimethoxy-2H-benzo[a]quinolizin-2-one
2-oxo-3-Isobutyl-9,10-dimethoxy-1,2,3,4,6,7-hexahydro-11BH-benzo[a]quinolizine
2-oxo-3-Isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-benzoquinolizine
Cambridge laboratories brand OF tetrabenazine
Nitoman
Nitoman®|Revocon®|Ro-19569|TBZ
NSC-169886
Orphan brand OF tetrabenazine
Regulin
REVOCON
Ro 1-9569
RO-19569
RO-1-9569
Roche brand OF tetrabenazine
Rubigen
|
Shire brand OF tetrabenazine
TBZ
TETMODIS
Tetra benazin
TETRABENAZINA
Tetrabenazina [inn-spanish]
Tetrabenazine
Tetrabenazine orphan brand
TETRABENAZINUM
Tetrabenazinum [inn-latin]
Tetrabenzaine
Tetrabenzine
Xenazine
XENAZINE 25
|
|
33 |
|
Piracetam |
Approved, Investigational |
Phase 3 |
|
7491-74-9 |
4843 |
Synonyms:
2-(2-Oxopyrrolidin-1-yl)ethanimidate
2-Pyrrolidone-N-acetamide
AbZ brand OF piracetam
Almirall brand OF piracetam
Alpharma brand OF piracetam
Avigilen
Axonyl
Azupharma brand OF piracetam
Cerebroforte
Cerepar N
Ciclofalina
CL-871
Cuxabrain
Dinagen
Gabacet
Geram
Hexal brand OF piracetam
Holsten brand OF piracetam
Hormona brand OF piracetam
memo Puren
memo-Puren
Merckle brand OF piracetam
Myocalm
Nootrop
NOOTROP 1200
|
NOOTROP 400
NOOTROP 800
Nootropil
Nootropil®
Nootropyl
Normabraïn
Pfizer brand OF piracetam
Piracebral
PIRACETAM
Piracetam abz
Piracetam RPH
Piracetam-RPH
Piracetamum
Piracetrop
Pirazetam
Pyracetam
Pyramem
Riemser brand OF piracetam
Rodleben brand OF piracetam
Sanofi synthelabo brand OF piracetam
Sinapsan
TAD brand OF piracetam
UCB brand OF piracetam
Vedim brand OF piracetam
|
|
34 |
|
Anti-Anxiety Agents |
|
Phase 3 |
|
|
|
35 |
|
Carbidopa, levodopa drug combination |
|
Phase 3 |
|
|
|
36 |
|
Analgesics |
|
Phase 3 |
|
|
|
37 |
|
Adjuvants, Immunologic |
|
Phase 3 |
|
|
|
38 |
|
Immunologic Factors |
|
Phase 3 |
|
|
|
39 |
|
Antiviral Agents |
|
Phase 3 |
|
|
|
40 |
|
Anti-Infective Agents |
|
Phase 3 |
|
|
|
41 |
|
Analgesics, Non-Narcotic |
|
Phase 3 |
|
|
|
42 |
|
Cardiac Glycosides |
|
Phase 3 |
|
|
|
43 |
|
Ginkgo |
|
Phase 3 |
|
|
|
Synonyms:
B1260
EGB 761
EGB-761
GINKGO
GINKGO BILOBA EXTRACT
|
GINKGO BILOBA LEAF
GINKGO BILOBA LEAF DRY EXTRACT
GINKGO BILOBA LEAF EXTRACT
GINKGO BILOBA LEAF TINCTURE
|
|
44 |
|
Neuroprotective Agents |
|
Phase 3 |
|
|
|
45 |
|
Phenylephrine |
Approved |
Phase 2 |
|
59-42-7 |
6041 |
Synonyms:
(-)-m-Hydroxy-a-(methylaminomethyl)benzyl alcohol
(-)-m-Hydroxy-alpha-(methylaminomethyl)benzyl alcohol
(−)-m-hydroxy-α-(methylaminomethyl)benzyl alcohol
(-)-m-Hydroxy-α-(methylaminomethyl)benzyl alcohol
(R)-3-[-1-HYDROXY-2-(METHYLAMINO)ETHYL]PHENOL
(R)-3-Hydroxy-alpha-((methylamino)methyl)benzenemethanol
AB-101 (PHENYLEPHRINE)
Adrianol
Ak-dilate
Ak-nefrin
Alcon efrin
Alconefrin nasal drops 12
Alconefrin nasal drops 25
Alconefrin nasal drops 50
Alconefrin nasal spray 25
BENZENEMETHANOL, 3-HYDROXY-.ALPHA.-[(METHYLAMINO)METHYL]-, (R)-
BENZENEMETHANOL, 3-HYDROXY-ALPHA-((METHYLAMINO)METHYL)-, (R)-
BENZYL ALCOHOL, M-HYDROXY-ALPHA-((METHYLAMINO)METHYL)-, (-)-
Biomydrin
CYCLOMYDRIL
Dilatair
Dimetane
Dionephrine
Doktors
DUO-MEDIHALER
Duration
Fenilefrina
Fenilefrina [INN-Spanish]
I-phrine
Isophrim
Isophrin
Isopto frin
J8.601K
L-(3-Hydroxyphenyl)-N-methylethanolamine
L-Phenylephedrine
L-Phenylephrine
Mesaton
Mesatone
Mesatonum
Metaoxedrin
Metaoxedrine
Metaoxedrinum
Metasympatol
Metasynephrine
|
Metsatonum
Mezaton
Minims phenylephrine
m-Methylaminoethanolphenol
m-Oxedrine
m-oxedrine|metasynephrine
m-Sympathol
m-Sympatol
m-Synephrine
Mydfrin
Neo synephrine
Neofrin
Neophryn
Neosynephrine
Neo-synephrine
Neo-synephrine nasal drops
Neo-synephrine nasal jelly
Neo-synephrine nasal spray
Neo-synephrine pediatric nasal drops
Nostril
Nostril spray pump
Nostril spray pump mild
Ocugestrin
Ocu-phrin sterile eye drops
Ocu-phrin sterile ophthalmic solution
PEF100
Phenoptic
PHENYLEPHRINE
Phenylephrine hydrochloride
Phenylephrine minims
Phenylephrine tannate
Phenylephrinum
Phenylephrinum [INN-Latin]
Prefrin
Prefrin liquifilm
Pyracort D
R(-)-Mezaton
R(-)-Phenylephrine
Relief eye drops for red eyes
Rhinall
Spersaphrine
Tannate, phenylephrine
Vicks sinex
Visadron
|
|
46 |
|
Oxymetazoline |
Approved, Investigational |
Phase 2 |
|
1491-59-4 |
4636 |
Synonyms:
2-(4-Tert-butyl-2,6-dimethyl-3-hydroxybenzyl)-2-imidazoline
3-[(4,5-Dihydro-1H-imidazol-2-yl)methyl]-6-(1,1-dimethylethyl)-2,4-dimethylphenol
6-t-Butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethylphenol
6-Tert-butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethylphenol
Afrin
Afrin®|oxymethazoline|SCH-9384|Upneeq® (opthalmic solution)|Vicks Sinex®
Hydrochloride, oxymetazoline
OCUCLEAR
Operil
Oximetazolinum
|
Oxymetazolina
OXYMETAZOLINE
Oxymétazoline
Oxymetazoline hydrochloride
Oxymetazoline hydrochloride crystalline
Oxymetazolinum
Oxymethazoline
Oxymetozoline
SCH-9384
VICKS SINEX
|
|
47 |
|
Amitriptyline |
Approved |
Phase 2 |
|
50-48-6 |
2160 |
Synonyms:
10,11-Dihydro-5-(gamma-dimethylaminopropylidene)-5H-dibenzo(a,D)cycloheptene
10,11-Dihydro-5-(g-dimethylaminopropylidene)-5H-dibenzo(a,D)cycloheptene
10,11-Dihydro-5-(γ-dimethylaminopropylidene)-5H-dibenzo(a,D)cycloheptene
10,11-Dihydro-N,N-dimethyl-5H-dibenzo(a,D)heptalene-Delta(5),gamma-propylamine
10,11-Dihydro-N,N-dimethyl-5H-dibenzo(a,D)heptalene-delta(5),g-propylamine
10,11-Dihydro-N,N-dimethyl-5H-dibenzo(a,D)heptalene-δ(5),g-propylamine
10,11-Dihydro-N,N-dimethyl-5H-dibenzo(a,D)heptalene-δ(5),γ-propylamine
10,11-dihydro-N,N-dimethyl-5H-dibenzo(a,d)heptalene-Δ5,γ-propylamine
3-(10,11-Dihydro-5H-dibenzo(a,D)cyclohepten-5-ylidene)-N,N-dimethyl-1-propanamine
3-(10,11-Dihydro-5H-dibenzo[a,D]cyclohepten-5-ylidene)-N,N-dimethylpropan-1-amine
5-(3-Dimethylaminopropylidene)-10,11-dihydro-5H-dibenzo(a,D)cycloheptatriene
5-(3-Dimethylaminopropylidene)-10,11-dihydro-5H-dibenzo(a,D)cycloheptene
5-(gamma-Dimethylaminopropylidene)-5H-dibenzo[a,D][1,4]cycloheptadiene
5-(g-Dimethylaminopropylidene)-5H-dibenzo[a,D][1,4]cycloheptadiene
5-(Γ-dimethylaminopropylidene)-5H-dibenzo[a,D][1,4]cycloheptadiene
Adepress
Adepril
Alphapharm brand OF amitriptyline hydrochloride
Amineurin
AMITID
AMITRIL
Amitrip
Amitriprolidine
Amitriptilina
Amitriptylin
Amitriptylin beta
Amitriptylin desitin
Amitriptylin neuraxpharm
Amitriptylin RPH
Amitriptyline
Amitriptyline HCL
Amitriptyline hydrochloride
Amitriptylinneuraxpharm
Amitriptylin-neuraxpharm
Amitriptylinum
Amitrol
Amitryptiline
amitryptiline|Elavil®|Endep®
Amitryptyline
Amrad brand OF amitriptyline hydrochloride
Amytriptiline
Anapsique
Apo amitriptyline
Apo-amitriptyline
ApoAmitriptyline
Apotex brand OF amitriptyline hydrochloride
APS brand OF amitriptyline hydrochloride
Bayer brand OF amitriptyline hydrochloride
beta, Amitriptylin
Betapharm brand OF amitriptyline hydrochloride
Cahill may roberts brand OF amitriptyline embonate
Cahill may roberts brand OF amitriptyline hydrochloride
Damilan
|
Damilen
dAmitriptyline
DDSA brand OF amitriptyline hydrochloride
Desitin brand OF amitriptyline hydrochloride
Desitin, amitriptylin
Domical
Douglas brand OF amitriptyline hydrochloride
Elanil
Elavil
Endep
ETRAFON-A
ETRAFON-FORTE
Flavyl
Goldshield brand OF amitriptyline hydrochloride
Hexal brand OF amitriptyline hydrochloride
Hexathane
Horizon
Krewel brand OF amitriptyline hydrochloride
Lantron
Laroxil
Laroxyl
Lentizol
LIMBITROL
Lundbeck brand OF amitriptyline hydrochloride
Merck brand OF amitriptyline hydrochloride
Merck sharp and dohme brand OF amitriptyline embonate
Merck sharp and dohme brand OF amitriptyline hydrochloride
Neuraxpharm brand OF amitriptyline hydrochloride
Neuro hexal brand OF amitriptyline hydrochloride
Novoprotect
Parke davis brand OF amitriptyline hydrochloride
Proheptadiene
Protea brand OF amitriptyline hydrochloride
Psicofarma brand OF amitriptyline hydrochloride
Redomex
Rhône poulenc rorer brand OF amitriptyline hydrochloride
Rhône-poulenc rorer brand OF amitriptyline hydrochloride
Roche brand OF amitriptyline hydrochloride
Rodleben brand OF amitriptyline hydrochloride
RPH, Amitriptylin
Saroten
Sarotex
Seroten
Sylvemid
Syneudon
Triptafen
Triptanol
Triptilin
Triptisol
Tryptanol
Tryptine
Tryptizol
Zeneca brand OF amitriptyline hydrochloride
|
|
48 |
|
Pimavanserin |
Approved, Investigational |
Phase 2 |
|
706779-91-1 |
10071196 |
Synonyms:
ACP 103
ACP 103|ACP-103|Nuplazid (proposed trade name)
ACP-103
Bis(1-(4-fluorobenzyl)-1-(1-methylpiperidin-4-yl)-3-(4-(2-methylpropoxy)benzyl)urea) (2R,3R)-2,3-dihydroxybutanedioate
N-(4-Fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-n'-(4-(2-methylpropyloxy)phenylmethyl) carbamide
|
N-(4-Fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-n'-(4-(2-methylpropyloxy)phenylmethyl)carbamide
Nuplazid
PIMAVANSERIN
Pimavanserin tartrate
Urea, N-((4-fluorophenyl)methyl)-N-(1-methyl-4-piperidinyl)-n'-((4-(2-methylpropoxy)phenyl)methyl)-, (2R,3R)-2,3-dihydroxybutanedioate (2:1)
|
|
49 |
|
Entacapone |
Approved, Investigational |
Phase 2 |
|
130929-57-6 |
5281081 |
Synonyms:
(e)-a-Cyano-N,N-diethyl-3,4-dihydroxy-5-nitrocinnamamide
(e)-alpha-Cyano-N,N-diethyl-3,4-dihydroxy-5-nitrocinnamamide
(e)-Α-cyano-N,N-diethyl-3,4-dihydroxy-5-nitrocinnamamide
2-Cyano-N,N-diethyl-3-(3,4-dihydroxy-5-nitrophenyl)propenamide
COM998
Comtan
Comtan®|Comtess®|OR-611
Comtess
Entacapona
|
Entacapona [INN-Spanish]
ENTACAPONE
Entacapone [Usan:Inn]
Entacaponum
Entacaponum [INN-Latin]
N,N-Diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl) acrylamide
Novartis brand OF entacapone
OR-611
Orion brand OF entacapone
|
|
50 |
|
Nicotine |
Approved |
Phase 1, Phase 2 |
|
54-11-5 |
942 89594 |
Synonyms:
(-)-3-(1-Methyl-2-pyrrolidyl)pyridine
(-)-3-(N-Methylpyrrolidino)pyridine
(−)-nicotine
(-)-Nicotine
(+-)-3-(1-Methyl-2-pyrrolidinyl)pyridine
(+)-Nicotine
(+-)-Nicotine
(R)-3-(1-Methyl-2-pyrrolidinyl)pyridine
(R,S)-Nicotine
(RS)-Nicotine
(S)-(−)-nicotine
(S)-(-)-Nicotine
(S)-3-(1-Methylpyrrolidin-2-yl)pyridine
(S)-3-(N-Methylpyrrolidin-2-yl)pyridine
(S)-Nicotine
1-Methyl-2-(3-pyridal)-pyrrolidene
1-Methyl-2-(3-pyridal)-pyrrolidine
1-Methyl-2-(3-pyridiyl)pyrrolidine
1-Methyl-2-(3-pyridyl)pyrrolidine
2'-beta-H-Nicotine
3-(1-Methyl-2-pyrollidinyl)pyridine
3-(1-Methyl-2-pyrrolidinyl)pyridine
3-(1-Methyl-2-pyrrolidinyl)-pyridine
3-(1-Methylpyrrolidin-2-yl)pyridine
3-(2-(N-Methylpyrrolidinyl))pyridine
3-(N-Methylpyrollidino)pyridine
3-(N-Methylpyrrolidino)pyridine
3-N-Methylpyrrolidine
a -N-Methylpyrrolidine
alpha-N-Methylpyrrolidine
a-N-Methylpyrrolidine
beta-Pyridyl-alpha-N-methylpyrrolidine
Bitartrate, nicotine
Black Leaf
Black Leaf 40
Campbell's Nico-Soap
Commit
delta-Nicotine
Destruxol
Destruxol Orchid Spray
DL-Tetrahydronicotyrine
D-Nicotine
Emo-Nik
Flux Maag
Fumeto bac
Fumetobac
Habitrol
L(−)-nicotine
L(-)-Nicotine
L-3-(1-Methyl-2-pyrrolidyl)pyridine
L-Nicotine
|
Mach-Nic
Methyl-2-pyrrolidinyl)pyridine
Niagara P.A. Dust
NICABATE
Nicocide
Nicoderm
NICODERM CQ
Nico-Dust
Nico-Fume
NICOPASS
NICOPATCH
Nicorette
NICORETTE INVISI
Nicorette Plus
Nicorette®|Nicotrol®
Nicotin
Nicotina
Nicotine
Nicotine alkaloid
Nicotine betadex
Nicotine bitartrate
Nicotine polacrilex
Nicotine tartrate
NICOTINELL CLASSIC
NICOTINELL SUPPORT
NICOTINELL TTS 10
NICOTINELL TTS 20
NICOTINELL TTS 30
NICOTROL
NICOTROL INHALER
NICOTROL NS
Nic-Sal
Nikotin
Nikotyna
NIQUITIN
NIQUITIN CLR
NIQUITIN MINIS CHERRY
NIQUITIN MINIS MINT
NIQUITIN MINIS ORANGE
NIQUITIN MINT
NIQUITIN PRE-QUIT
NIQUITIN STRIPS MINT
Ortho N-4 Dust
Ortho N-5 Dust
PROSTEP
R)-(+)-Nicotine
STOPPERS
STUBIT
Tartrate, nicotine
Tendust
|
|
Interventional clinical trials:
(show top 50)
(show all 239)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Aripiprazole for Pre-Existing Neuroleptic-Induced Tardive Dyskinesia: a Prospective 26-Week Observational Study |
Unknown status |
NCT00837707 |
Phase 4 |
aripiprazole |
2 |
The Monitor of Serum Prolactin Level and Related Clinical Observations Among Individuals With Schizophrenia Spectrum Illnesses in a 3 Months Aripiprazole Trial |
Unknown status |
NCT00468533 |
Phase 4 |
Aripiprazole |
3 |
Effect of Varenicline on Smoking Cessation in Patients With Schizophrenia: Evaluation of Antipsychotic Drug-Induced Neurological Symptoms as Correlates of Response |
Unknown status |
NCT03495024 |
Phase 4 |
Varenicline |
4 |
Different Dyskinesias in Parkinson's Disease and Their Relation to Levodopa Pharmacokinetics |
Completed |
NCT00888186 |
Phase 4 |
levodopa/carbidopa |
5 |
Efficacy and Safety of Levetiracetam Versus Placebo on Levodopa-induced Dyskinesias in Advanced Parkinson's Disease (LeLeDys Study) - A Multicenter, Randomized, Stratified, Double-blinded, Placebo-controlled Phase IV Study |
Completed |
NCT00307450 |
Phase 4 |
Levetiracetam |
6 |
A Phase 4, Double-Blind, Placebo-Controlled, Randomized Withdrawal Study to Evaluate the Persistence of Effect and Safety of Valbenazine for the Treatment of Tardive Dyskinesia |
Completed |
NCT03891862 |
Phase 4 |
Valbenazine;Placebo oral capsule |
7 |
A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Potential for Clinical Dependence and Withdrawal Symptoms Associated With Valbenazine |
Completed |
NCT03698331 |
Phase 4 |
Valbenazine;Placebo oral capsule |
8 |
A Double-Blind, Randomised, Parallel-Group Comparison of Ethyl-Eicosapentaenoic Acid (Ethyl-EPA) Versus Placebo as Add-on Medication in Patients With Established Tardive Dyskinesia |
Completed |
NCT00114595 |
Phase 4 |
eicosapentaenoic acid |
9 |
Tardive Dyskinesia and Cognitive Function |
Completed |
NCT00926965 |
Phase 4 |
amisulpride;Olanzapine;Conventional antipsychotics |
10 |
Treatment of Tardive Dyskinesia With Galantamine |
Completed |
NCT00164242 |
Phase 4 |
Galantamine |
11 |
Validation of Dyskinesia Rating Scales |
Completed |
NCT01071395 |
Phase 4 |
Amantadine;Placebo |
12 |
A Randomized Controlled Trial of Risperidone and Olanzapine for the Schizophrenic Patients With Neuroleptic-Induced Tardive Dyskinesia |
Completed |
NCT00621998 |
Phase 4 |
risperidone;olanzapine |
13 |
An Open-Label Tolerability and Exploratory Efficacy Study of Zonisamide for Dyskinesias in Parkinson's Disease |
Suspended |
NCT03034538 |
Phase 4 |
Zonegran |
14 |
Botulinum Toxin Type A (Botox) in the Management of Levodopa-Induced Peak-Dose Dyskinesias in Parkinson's Disease: A Double-Blind, Randomized, Placebo Controlled, Cross-Over Design Study |
Terminated |
NCT00477802 |
Phase 4 |
|
15 |
Buspirone Treatment of Iatrogenic Dyskinesias in Advanced Parkinson' Disease. Multicenter, International, Placebo-controlled, Randomised, Double Blind Trial |
Unknown status |
NCT02617017 |
Phase 3 |
Buspirone;Placebo |
16 |
Open Label Prospective Study of High Dose Ropinirole for Motor Fluctuations and Dyskinesias in Advanced Parkinson's Disease |
Unknown status |
NCT00260793 |
Phase 3 |
Ropinirole Hydrochloride |
17 |
A Two Year Phase IIIb Randomised, Multicenter, Double-blind, SINEMET Controlled, Parallel Group, Flexible Dose Study, to Assess the Effectiveness of Controlled Release Ropinirole add-on Therapy to L-dopa at Increasing the Time to Onset of Dyskinesia in Parkinson's Disease Subjects. |
Completed |
NCT00363727 |
Phase 3 |
ropinirole controlled-release (REQUIP CR) for RLS |
18 |
Open-Label, 12-Month Safety and Efficacy Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Disease Subjects |
Completed |
NCT00360568 |
Phase 3 |
Levodopa-carbidopa intestinal gel |
19 |
A Double-Blind, Randomised, Parallel-Group Comparison of Extract of Ginkgo Biloba(EGB-761) Versus Placebo as Add-on Medication in Patients With Established Tardive Dyskinesia |
Completed |
NCT00672373 |
Phase 3 |
Extract of Ginkgo Biloba (EGb-761 capsules);Placebo |
20 |
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia |
Completed |
NCT02291861 |
Phase 3 |
SD-809;Placebo |
21 |
Open-Label Rollover Study for Continuing Valbenazine (NBI-98854) Administration for the Treatment of Tardive Dyskinesia |
Completed |
NCT02736955 |
Phase 3 |
Valbenazine |
22 |
An Open-label, Randomized 12 Week Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levodopa Enteral Suspension and Optimized Medical Treatment on Dyskinesia in Subjects With Advanced Parkinson's Disease DYSCOVER (DYSkinesia COmparative Interventional Trial on Duodopa VERsus Oral Medication) |
Completed |
NCT02799381 |
Phase 3 |
Optimized antiparkinsonian treatment;Levodopa-Carbidopa Intestinal Gel (LCIG) |
23 |
ADS-5102 (Amantadine HCl) Extended Release Efficacy and Safety Study in Parkinson's Disease Patients With Levodopa-Induced Dyskinesia (EASE LID 3 Study) |
Completed |
NCT02274766 |
Phase 3 |
ADS-5102 |
24 |
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia |
Completed |
NCT02274558 |
Phase 3 |
NBI-98854;Placebo |
25 |
A Randomized, Double-Blind, Placebo-Controlled Study of TEV-50717 (Deutetrabenazine) for the Treatment of Dyskinesia in Cerebral Palsy in Children and Adolescents |
Completed |
NCT03813238 |
Phase 3 |
Deutetrabenazine;Placebo |
26 |
Efficacy and Safety of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia in Parkinson's Disease Patients (EASE LID Study) |
Completed |
NCT02136914 |
Phase 3 |
ADS-5102 |
27 |
A Double-blind, Placebo-controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan HCl 1 mg b.i.d. in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia |
Completed |
NCT00105508 |
Phase 3 |
Sarizotan;Placebo |
28 |
A Double-Blind, Randomized, Multicenter, Placebo-Controlled, Parallel, Fixed-Dose Study to Evaluate the Efficacy and Safety of MT-5199 for the Treatment in Patients With Tardive Dyskinesia (J-KINECT) |
Completed |
NCT03176771 |
Phase 2, Phase 3 |
MT-5199;Placebo |
29 |
Therapeutic Use of Piracetam for Treatment of Patients Suffering From Tardive Dyskinesia: a Double Blind, Placebo-Controlled Crossover Study |
Completed |
NCT00190008 |
Phase 3 |
piracetam |
30 |
A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia |
Completed |
NCT00105521 |
Phase 3 |
Sarizotan;Placebo |
31 |
A Phase 3, Open-Label, Safety and Tolerability Study of NBI-98854 for the Treatment of Tardive Dyskinesia |
Completed |
NCT02405091 |
Phase 3 |
NBI-98854 |
32 |
Levetiracetam Treatment of Tardive Dyskinesia |
Completed |
NCT00291213 |
Phase 3 |
levetiracetam;placebo |
33 |
Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia (EASED Study) |
Completed |
NCT01397422 |
Phase 2, Phase 3 |
ADS-5102 (extended release amantadine HCl) |
34 |
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID) |
Completed |
NCT02202551 |
Phase 3 |
ADS-5102 |
35 |
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia |
Completed |
NCT02198794 |
Phase 3 |
SD-809;Placebo |
36 |
A Randomized, Double-Blind, Placebo-Controlled Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia |
Completed |
NCT02195700 |
Phase 2, Phase 3 |
SD-809;Placebo |
37 |
Study of Efficacy and Acceptability of Tetrabenazine in the Late Dyskinetic Syndrome With Neuroleptics: A Randomized, Parallel Group, Double-blind Placebo Controlled Multicentre Trial |
Completed |
NCT01543321 |
Phase 3 |
Tetrabenazine;Placebo |
38 |
Phase 2b/3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Dipraglurant (ADX48621) for the Treatment of Dyskinesia in Patients With Parkinson's Disease Receiving Levodopa-based Therapy |
Recruiting |
NCT04857359 |
Phase 2, Phase 3 |
Dipraglurant;Placebo |
39 |
An Open-label Safety Study of Dipraglurant (ADX48621) in Patients With Parkinson's Disease Receiving Levodopa-based Therapy With or Without Concomitant Dopaminergic Medications |
Recruiting |
NCT05116813 |
Phase 2, Phase 3 |
Dipraglurant |
40 |
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy |
Recruiting |
NCT05206513 |
Phase 3 |
Placebo;Valbenazine |
41 |
A Multicenter, Randomized, Placebo-controlled, Double-blind, 16 Week Study to Evaluate the Efficacy and Safety of Amantadine HCl Extended Release Tablets in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesias |
Terminated |
NCT02153645 |
Phase 3 |
240mg Amantadine HCl ER tablets;Placebo tablets;320mg Amantadine HCl ER tablets |
42 |
A Multicenter, Randomized, Placebo-controlled, Double-blind, 26 Week Study to Evaluate the Efficacy and Safety of Amantadine HCl Extended Release Tablets in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesias |
Terminated |
NCT02153632 |
Phase 3 |
amantadine HCl ER;Placebo |
43 |
Pyridoxal Kinase Activity in Schizophrenia Patients Without Versus With Tardive Dyskinesia Treated With Vitamin B6 |
Withdrawn |
NCT01908452 |
Phase 3 |
Pyridoxine |
44 |
Safety and Efficacy of Propranolol in the Treatment of Tardive Dyskinesia |
Withdrawn |
NCT03254186 |
Phase 2, Phase 3 |
Propranolol Hydrochloride;Placebo Oral Tablet |
45 |
A Phase 3, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of 2 Doses of Safinamide Compared to Placebo in the Treatment of LID in PD Patients With Motor Fluctuations |
Withdrawn |
NCT03987750 |
Phase 3 |
Safinamide Methanesulfonate 150mg;Safinamide Methanesulfonate 100mg;Safinamide Methanesulfonate matching placebo |
46 |
Levetiracetam Administration for the Management of Levodopa-Induced Dyskinesias in Parkinson's Disease: A Double-Blind,Placebo-Controlled, Crossover Trial |
Unknown status |
NCT00291733 |
Phase 2 |
Levetiracetam;Placebo |
47 |
Randomized, Double-Blind, Placebo-Controlled Trial on the Efficacy of Omega-3 Supplementation With Docosahexaenoic Acid (DHA) on Tardive Dyskinesia |
Unknown status |
NCT00621634 |
Phase 2 |
|
48 |
Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, 4-way Crossover, Dose-finding Study, of Eltoprazine Safety, Tolerability and Efficacy in the Treatment of Levodopa-induced Dyskinesia in Patients With Parkinson's Disease |
Unknown status |
NCT02439125 |
Phase 2 |
Eltoprazine HCl;Placebo |
49 |
Randomized Controlled Trial of Laparoscopic Cholecystectomy vs. Non-operative Treatment for Gallbladder Dyskinesia |
Unknown status |
NCT02195115 |
Phase 2 |
amitriptyline |
50 |
A Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multiple Oral Dose Study to Assess the Efficacy and Tolerability of AFQ056 in Reducing L-dopa Induced Dyskinesias in Parkinson's Patients With Severe L-dopa Induced Dyskinesias |
Completed |
NCT00888004 |
Phase 2 |
AFQ056;Placebo |
Cochrane evidence based reviews: dyskinesias
|